New meningitis vaccine enters first human tests
NCT ID NCT07374510
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new vaccine designed to protect against several types of meningococcal bacteria, which can cause meningitis and bloodstream infections. Researchers will enroll 150 healthy people aged 2 to 59 to check the vaccine's safety and how well it triggers an immune response. Participants will receive different doses of the experimental vaccine, an existing vaccine, or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Group ACYW135X Meningococcal Conjugate Vaccine
- What this could lead to
- If successful, this could lead to a new vaccine that protects against several types of meningococcal bacteria, which cause serious infections like meningitis.
- What could go wrong
- This is an early Phase 1 trial with only 150 participants, so it is primarily checking safety and immune response. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.